Selected Gilead Abstracts Published at AIDS 2020
The abstracts selected by Gilead Medical Affairs Germany for AIDS 2020 cover a range of topics related to HIV treatment and research. Topics include safety and efficacy of B/F/TAF in older adults, real-world effectiveness of B/F/TAF in clinical practice, prevalence of resistance in PLWH, and the latest advancements in HIV cure agents. These abstracts showcase important findings and advancements in the field of HIV research presented at the Virtual AIDS 2020 conference.
Download Presentation
Please find below an Image/Link to download the presentation.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author. Download presentation by click this link. If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.
E N D
Presentation Transcript
Selected Gilead-initiated or Gilead-supported Abstracts Published at AIDS 2020 Abstracts selected by Gilead Medical Affairs Germany, July 3rd 1
Virtual AIDS 2020, 6 - 10 July 2020 Selected Gilead-initiated/supported abstracts B/F/TAF Title Speaker Link to Presentation Link to Session Pooled analysis of 4 international trials of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults aged >65 or older demonstrating safety and efficacy: Week 48 results OA-B-04 Moti Ramgopal Oral OAB0403 Antiretrovirals session 2 The BICSTaR prospective cohort: Real-world effectiveness, safety and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in routine clinical practice in people living with HIV (PLWH) Olivier Robineau Poster PEB0229 E-posters Track B Prevalence and risk factors of pre-existing NNRTI resistance among suppressed PLWH in B/F/TAF switch studies Kristen Andreatta Poster PEB0254 E-posters Track B Baseline NRTI resistance in suppressed participants did not lead to viral blips on bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) or dolutegravir (DTG)+F/TAF through week 48 in study 380-4030 Rima Acosta Poster PEB0257 E-posters Track B Links behind abstract number in column Link to Presentation guide you to the on-demand presentation just click on the abstract number Links in column Link to Session guide you to the online program just click on the session number Not all Internet Browser seem to work, please test different Internet Browsers in case content is not displayed 2
Virtual AIDS 2020, 6 - 10 July 2020 Selected Gilead-initiated/supported abstracts E/C/F/TAF Title Speaker Link to Presentation Link to Session Late Breaker Oral OABLB0101 Thu, July 9 2:00 PM (GMT-7) OA-B-LB-01 Track B late-breaker abstracts Safety, pharmacokinetics and efficacy of low-dose E/C/F/TAF in virologically suppressed children 2 years old living with HIV Eva Natukunda Capsid Inhibitor Lenacapavir (LEN, formerly GS-6207) Title Speaker Link to Presentation Link to Session GS-6207 sustained delivery formulation supports 6-month dosing interval Rebecca Begley Poster PEB0265 E-posters Track B HIV Cure Agent Vesatolimod (VES, formerly GS-9620) Title Speaker Link to Presentation Link to Session OA-B-02 Vesatolimod, a toll-like receptor 7 (TLR7) agonist, induces dose-dependent immune responses in HIV controllers Jeffrey Wallin Oral OAB0205 ARV, cure and testing strategies Links behind abstract number in column Link to Presentation guide you to the on-demand presentation just click on the abstract number Links in column Link to Session guide you to the online program just click on the session number Not all Internet Browser seem to work, please test different Internet Browsers in case content is not displayed 3
Virtual AIDS 2020, 6 - 10 July 2020 Selected Gilead-initiated/supported abstracts F/TAF for PrEP Title Speaker Link to Presentation Link to Session Persistently high rates of sexually transmitted infections in the DISCOVER HIV PrEP trial Poster Discussion PDB0303 PD-B-03 Linda Gorgos Opportunistic infections Deep sequencing with unique molecular identifiers for evaluation of HIV-1 drug resistance in the DISCOVER pre-exposure prophylaxis trial Poster Discussion PDB0404 PD-B-04 Resistance Stephanie Cox Discover study for HIV Pre-Exposure Prophylaxis (PrEP): No evidence of risk compensation in participants taking F/TDF or F/TAF for PrEP through 96 weeks Peter Shalit Poster PEB0165 E-posters Track B Links behind abstract number in column Link to Presentation guide you to the on-demand presentation just click on the abstract number Links in column Link to Session guide you to the online program just click on the session number Not all Internet Browser seem to work, please test different Internet Browsers in case content is not displayed 4
Virtual AIDS 2020, 6 - 10 July 2020 Selected Gilead-initiated/supported abstracts HIV Treatment Including Comorbidities Title Speaker Link to Presentation Link to Session Reducing ART to less than 3-ARV regimen linked to increased systemic inflammation Sergio Serrano- Villar OA-B-03 Oral OAB0304 Antiretrovirals session 1 PD-A-01 Modelling endothelial function in vitro and via blood sampling to assess cardiovascular risk in people living with HIV Poster Discussion PDA0105 Akif A. Khawaja HIV, co-infection and co- morbidities Patterns of antiretroviral use and immunologic correlates in the REPRIEVE trial at study entry Carl J Fichtenbaum Poster PEB0181 E-posters Track B HIV and comorbidities: The impact of comorbidities on health-related quality of life in people living with HIV in Italy Lucrezia Ferrario, Poster PED0833 E-posters Track D Links behind abstract number in column Link to Presentation guide you to the on-demand presentation just click on the abstract number Links in column Link to Session guide you to the online program just click on the session number Not all Internet Browser seem to work, please test different Internet Browsers in case content is not displayed 5
Virtual AIDS 2020, 6 - 10 July 2020 Selected Gilead-initiated/supported abstracts HIV Treatment Including Comorbidities Title Speaker Link to Presentation Link to Session Third-line antiretroviral therapy including raltegravir, darunavir/ritonavir and/or etravirine is well tolerated and achieves durable virologic suppression over 144+ weeks in resource limited settings ACTG: A5288 strategy trial Anchalee Avihingsanon OA-B-04 Oral OAB0404 Antiretrovirals session 2 OA-E-04 Innovation in initiation, treatment and care: Differentiated Service Delivery POP-UP clinic: A multicomponent model of care for people living with HIV (PLHIV) who experience homelessness or unstable housing (HUH) Elizabeth Imbert Oral OAE0406 Hair concentration of antiretroviral drugs, but not self-reported adherence, is associated with ongoing virologic failure among individuals in Resource Limited Settings (RLS) on second line Antiretroviral Therapy (ART) Tanakorn Apornpong Poster PEB0245 E-posters Track B Links behind abstract number in column Link to Presentation guide you to the on-demand presentation just click on the abstract number Links in column Link to Session guide you to the online program just click on the session number Not all Internet Browser seem to work, please test different Internet Browsers in case content is not displayed 6
Virtual AIDS 2020, 6 - 10 July 2020 Selected Gilead-initiated/supported abstracts HIV Treatment Including Comorbidities Title Speaker Link to Presentation Link to Session OA-B-06 Changes in body mass index over time in persons with and without HIV Michael Silverberg Oral OAB0603 Weight and metabolic changes & ART Late Breaker Oral OABLB0103 Thu, July 9 2:00 PM (GMT-7) OA-B-LB-01 Track B late-breaker abstracts The predicted risk of adverse pregnancy outcomes from treatment-induced obesity in the ADVANCE trial Sumbul Fatima Asif Late Breaker Oral OAXLB0104 Wed, July 8 2:01 PM (GMT-7) The ADVANCE trial: Phase 3, randomised comparison of TAF/FTC+DTG, TDF/FTC+DTG or TDF/FTC/EFV for first-line treatment of HIV-1 infection OA-X-LB-01 Co-Chairs' Choice Simiso Sokhela Links behind abstract number in column Link to Presentation guide you to the on-demand presentation just click on the abstract number Links in column Link to Session guide you to the online program just click on the session number Not all Internet Browser seem to work, please test different Internet Browsers in case content is not displayed 7
Virtual AIDS 2020, 6 - 10 July 2020 Selected Gilead-initiated/supported abstracts Testing, Test and Treat, Rapid Start Title Speaker Link to Presentation Link to Session OA-C-02 Geographic hotspots of high population HIV viremia and association with HIV incidence in a universal test-and-treat setting in rural Uganda and Kenya James Peng Oral OAC0203 Can we achieve UTT? What can UTT achieve? Evaluation of an emergency department-based opt-out HIV screening program in South Florida Paula A Eckardt Poster PEB0107 E-posters Track B Prevalence of HIV and other sexually transmitted infections among young Thai men and transgender women selling or trading sex in the COPE4YMSM study Andrew Hickey Poster PEC0409 E-posters Track C The UCSF Acute HIV Cohort: High virologic suppression and long-term retention rates in a contemporary San Francisco Bay Area cohort of acute HIV-infected individuals receiving immediate ART at diagnosis Sulggi Lee Poster PEC0483 E-posters Track C Characterizing new HIV infections within SEARCH, a universal test and treat trial in rural East Africa Marilyn Nyabuti Poster PEC0708 E-posters Track C "Why start later if I can start today?" Patient perspectives on the experience of rapid/same-day linkage and antiretroviral therapy after HIV diagnosis Katerina A. Christopoulos Poster PED0809 E-posters Track D Links behind abstract number in column Link to Presentation guide you to the on-demand presentation just click on the abstract number Links in column Link to Session guide you to the online program just click on the session number Not all Internet Browser seem to work, please test different Internet Browsers in case content is not displayed 8
Virtual AIDS 2020, 6 - 10 July 2020 Selected Gilead-initiated/supported abstracts Prevention including PrEP Title Speaker Link to Presentation Link to Session Lower than expected HIV incidence among men and women at elevated HIV risk in a population-based PrEP study in rural Kenya and Uganda: Interim results from the SEARCH study OA-C-08 PrEP at Scale Catherine Koss Oral OAC0805 Late Breaker Oral OACLB0101 Thu, July 9 1:01 AM (GMT-7) HPTN 083 interim results: Efficacy of pre-exposure prophylaxis (PrEP) containing long-acting injectable cabotegravir (CAB-LA) is maintained across regions and key populations OA-C-LB-01 Track C late-breaker abstracts Beatriz Grinsztejn Late Breaker Oral OADLB0101 Wed, July 8 1:01 AM (GMT-7) OA-D-LB-01 Track D late-breaker abstracts Impact of COVID-19 related shelter-in-place orders on PrEP access, usage and HIV risk behaviors in the United States Scott Brawley Late Breaker Oral OAXLB0101 Wed, July 8 2:01 PM (GMT-7) HPTN083 interim results: Pre-exposure prophylaxis (PrEP) containing long-acting injectable cabotegravir (CAB-LA) is safe and highly effective for cisgender men and transgender women who have sex with men (MSM,TGW) OA-X-LB-01 Co-Chairs' Choice Raphael Landovitz Links behind abstract number in column Link to Presentation guide you to the on-demand presentation just click on the abstract number Links in column Link to Session guide you to the online program just click on the session number Not all Internet Browser seem to work, please test different Internet Browsers in case content is not displayed 9
Virtual AIDS 2020, 6 - 10 July 2020 Selected Gilead-initiated/supported abstracts Prevention including PrEP Title Speaker Link to Presentation Link to Session Food insecurity highly prevalent and associated with early PrEP non-adherence among trans and non-binary people in the San Francisco Bay Area: The STAY Study PD-C-02 Poster Discussion PDC0203 Albert Liu Gaps in our response: Who are we missing? PD-C-04 Untangling the web of sexual reproductive health and sex differences in prevention Preventing HIV and achieving pregnancy among HIV-discordant couples using safer conception strategies in Zimbabwe Poster Discussion PDC0402 Joelle Brown High risk pregnant women initiation and persist on PrEP in Cape Town, South African cohort Dvora Joseph Davey Late Breaker Poster LBPEC24 Track C late-breaker posters "Even if you get raped you are protected": Results from a mixed-methods, multi-site study of PrEP engagement among transgender women in South Africa Tonia Poteat Poster PEC0405 E-posters Track C Factors affecting PrEP uptake and time to initiation among transgender participants in the TRIUMPH PrEP demonstration project in Oakland and Sacramento, California Jae Sevelius Poster PEC0595 E-posters Track C Links behind abstract number in column Link to Presentation guide you to the on-demand presentation just click on the abstract number Links in column Link to Session guide you to the online program just click on the session number Not all Internet Browser seem to work, please test different Internet Browsers in case content is not displayed 10
Virtual AIDS 2020, 6 - 10 July 2020 Selected Gilead-initiated/supported abstracts Prevention including PrEP Title Speaker Link to Presentation Link to Session Pre-exposure prophylaxis among Brazilian transwomen: Retention and adherence in 48 weeks follow-up of PrEParadas study Emilia Jalil Poster PEC0604 E-posters Track C Long-term patterns of PrEP adherence and association with HIV seroconversion in a large-scale implementation study in New South Wales (EPIC-NSW), Australia Fengyi Jin Poster PEC0627 E-posters Track C Uptake and outcomes of a novel community-based post-exposure prophylaxis (PEP) program in rural Kenya and Uganda James Ayieko Poster PEC0655 E-posters Track C Utility of PSA to assess self-reported protected sex among HIV discordant couples Allen Matubu Poster PEC0658 E-posters Track C Expanding the reach of pre-exposure prophylaxis to trans and non-binary communities in the San Francisco Bay Area: Development and evaluation of the STAY Study PrEP Campaign Erin C. Wilson Poster PEC0676 E-posters Track C Feasibility and acceptability of HIV prevention research among young transgender women who sell or trade sex in Bangkok and Pattaya, Thailand Tareerat Chemnasiri Poster PED1105 E-posters Track D Links behind abstract number in column Link to Presentation guide you to the on-demand presentation just click on the abstract number Links in column Link to Session guide you to the online program just click on the session number Not all Internet Browser seem to work, please test different Internet Browsers in case content is not displayed 11
Selected Gilead-initiated or Gilead-supported Abstracts Published at COVID-19 Conference Abstracts selected by Gilead Medical Affairs Germany, July 3rd 12
Virtual COVID-19 Conference, 10 11 July 2020 Selected Gilead-initiated/supported abstracts COVID-19 / Remdesivir Title Speaker Abstract Link to Session Oral Baseline characteristics associated with clinical improvement and mortality in hospitalized patients with severe COVID-19 treated with Remdesivir Kristen Marks Fri, July 10 11:00 AM (GMT-7) Remdesivir for severe COVID-19 versus a cohort receiving standard of care Susan Olender Poster Track B: Compassionate use of remdesivir in children with severe COVID-19 Kathleen Chiotos Poster Clinical science, testing (RT-PCR and serologic) and diagnoses, natural history, clinical care, ARDS care, therapeutics Compassionate use of remdesivir in pregnant women with severe COVID-19 Richard Burwick Poster Association between concomitant hydroxychloroquine use and safety and efficacy of remdesivir in severe COVID-19 patients George Diaz Poster Exposure to remdesivir through compassionate use: Safety and efficacy in 163 patients Renato Maserati Poster Racial/ethnic disparities not observed in clinical outcomes with remdesivir treatment Kathleen Mullane Poster 13
